✦ LIBER ✦

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

✍ Scribed by Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka

Book ID: 117785226
Publisher: The Lancet
Year: 2010
Tongue: English
Weight: 239 KB
Volume: 11
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(09)70364-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gefitinib versus cisplatin plus docetaxe

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

✍ Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamot 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 239 KB

Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib. However, whether gefitinib is better than standard platinum doublet chemotherapy in patients selected by

PCN17 Indirect Comparison of the Efficac

PCN17 Indirect Comparison of the Efficacy of Erlotinib Versus Pemetrexed Plus Cisplatin as First Line Treatment in Patients With Metastatic Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutations

✍ C. Pereira; M. Sanches; J.F. Loff 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB